Acute promyelocytic leukaemia in the all trans retinoic acid era.
Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.
DeLoughery
T G
TG
Oregon Health Sciences University, Portland 97201, USA.
Goodnight
S H
SH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000150:complications*; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D006487:Hemostasis; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications* / Q000188:drug therapy*; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin